Calcipotriol
Small molecule targets TSLP
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | SORILUX | — | 2012-09-27 – 2019-11-05 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | DOVONEX | — | 1996-08-15 – 1999-07-07 | fda.gov ↗ |
| Approved | US (FDA) | DOVONEX | — | 1993-12-29 | fda.gov ↗ |
Trials 94 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT05416320 | Aug → Nov 2023 | central centrifugal cicatricial alopecia | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 0 | NCT04839731 | Apr 2021 → Dec 2023 | skin squamous cell carcinoma | Carilion Clinic | Unknown | No outcome recorded |
| Phase 0 | NCT03996252 | Jul 2019 → Jan 2020 | actinic keratosis | Tulane University | Terminated | No outcome recorded |
| Phase 0 | NCT02411643 | Mar 2015 → Apr 2016 | localized scleroderma | Northwestern University | Terminated | No outcome recorded |
| Phase 0 | NCT02019355 | Oct 2013 → Mar 2015 | actinic keratosis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 126 trials | ||||||
| Phase 1 | NCT03898583 | Apr → Oct 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03892564 | Feb → Mar 2019 | phototoxic dermatitis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03899064 | Feb → Apr 2019 | photoallergic dermatitis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03596073 | Nov 2018 → Aug 2020 | breast cancer | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT03758365 | Nov 2018 | vascular disorder | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03370406 | Aug 2018 → Sep 2027 expected | squamous cell carcinoma | Melissa Pugliano-Mauro | Recruiting | No outcome recorded |
| Phase 1 | NCT03469336 | Apr 2018 → Mar 2019 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03476746 | Mar → Jul 2018 | — | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03442244 | Jan → Feb 2018 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03234673 | Aug 2017 → Aug 2018 | generalized vitiligo | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT03122353 | Apr → Nov 2017 | psoriasis | Tolmar Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02973776 | Dec 2016 → Feb 2017 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02379793 | Mar → Apr 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02193815 | Sep 2014 → Feb 2015 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02976727 | May 2014 → Aug 2015 | actinic keratosis | Dong-A University | Completed | No outcome recorded |
| Phase 1 | NCT01582932 | Apr 2013 → Aug 2018 | psoriasis | Mayne Pharma International Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01837576 | Apr → Jun 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01743118 | Mar → Jul 2013 | psoriasis | Circassia Limited | Completed | No outcome recorded |
| Phase 1 | NCT01646567 | Sep → Nov 2012 | psoriasis | TetraLogic Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01563068 | Apr 2012 → Aug 2015 | psoriasis | Mayne Pharma International Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01580488 | Apr → Jun 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01466478 | Nov → Dec 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01297166 | Feb → Apr 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01105234 | Apr → May 2010 | irritant dermatitis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01105286 | Apr → May 2010 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01043224 | Jan → Mar 2010 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03392311 | Jul → Oct 2019 | poisoning, psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT05488990 | Mar → Jun 2013 | psoriasis | Lipidor AB | Completed | No outcome recorded |
| Phase 1/2 | NCT01768013 | Jul → Oct 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 221 trials | ||||||
| Phase 2 | NCT04329221 | Jan 2026 → Jan 2029 | actinic keratosis, skin squamous cell carcinoma | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT04642287 | Jan 2026 → Jan 2029 | actinic keratosis, disease related to solid organ transplantation, skin squamous cell carcinoma | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT05699603 | Jul 2024 → Feb 2027 expected | actinic keratosis | University of Arizona | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04580537 | Oct 2020 → Jun 2021 | psoriasis | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03819218 | Dec 2018 → Dec 2020 | psoriasis | MC2 Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT03584360 | Sep 2018 | psoriasis | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 2 | NCT03462927 | Feb → Aug 2018 | psoriasis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02038569 | Jan 2014 → Feb 2018 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01600222 | May 2012 → May 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01229098 | Oct 2010 → Sep 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01120223 | May 2010 → Aug 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01083758 | Apr 2010 → Aug 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01268527 | Mar → Dec 2010 | psoriasis | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00817219 | Jul 2009 → Dec 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00875277 | Apr → May 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00704262 | May 2008 → Dec 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00820950 | May 2007 → Jan 2009 | psoriasis | Incyte Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00404196 | Oct 2006 → Mar 2007 | hand dermatosis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00392067 | Oct 2006 → Jun 2007 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00263718 | Dec 2005 → May 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00445250 | — | radiodermatitis | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05381597 | Oct 2022 → Jun 2027 expected | skin squamous cell carcinoma in situ, superficial multifocal basal cell carcinoma | Boston University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01694433 | Feb 2013 → Jan 2014 | acne | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT06851507 | Oct 2025 → Aug 2027 expected | actinic keratosis | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05249972 | Jan → Aug 2022 | psoriasis | Lipidor AB | Unknown | No outcome recorded |
| Phase 3 | NCT03806790 | Jan → Jun 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT03802344 | Dec 2018 → Oct 2019 | psoriasis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03731091 | Oct 2018 → Mar 2020 | psoriasis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT05174598 | Oct 2018 → Nov 2019 | psoriasis | Cadila Pharnmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02668692 | Feb → Jun 2016 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01866163 | Jun → Oct 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01188928 | Sep 2010 → Mar 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01139580 | May → Dec 2010 | psoriasis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00691002 | May 2008 → Jan 2010 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00688519 | Mar → Dec 2008 | psoriasis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00689481 | Mar → Oct 2008 | psoriasis | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00640822 | Feb 2008 → Jun 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00279162 | Dec 2005 → Jul 2007 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00243464 | Sep 2005 → May 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00216840 | Dec 2004 → Sep 2005 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00216827 | Nov 2004 → Sep 2005 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07453238 | Apr → Oct 2026 expected | alopecia areata | Hayat Abad Medical Complex, Peshawar | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06499415 | Sep 2024 → Mar 2029 expected | actinic keratosis | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04227288 | Nov 2021 → Oct 2023 | psoriasis | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT04555707 | Jun 2020 → Jun 2021 | psoriasis | Derm Research, PLLC | Unknown | No outcome recorded |
| Phase 4 | NCT04372277 | Apr 2020 → Mar 2021 overdue | psoriasis | Psoriasis Treatment Center of Central New Jersey | Recruiting | No outcome recorded |
| Phase 4 | NCT03827876 | Jan → Sep 2019 overdue | psoriasis | Psoriasis Treatment Center of Central New Jersey | Recruiting | No outcome recorded |
| Phase 4 | NCT03506477 | May 2018 → Sep 2019 | psoriasis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT03848871 | Dec 2017 → Nov 2018 | psoriasis | Derm Research, PLLC | Completed | No outcome recorded |
| Phase 4 | NCT03080545 | May → Oct 2017 | psoriasis | Psoriasis Treatment Center of Central New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT01761019 | Jan 2013 → Sep 2014 | psoriasis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00437619 | Feb 2007 → Aug 2009 | psoriasis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00248456 | Oct 2005 → Feb 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 4 | NCT00216892 | Apr → Dec 2005 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06737406 | May 2025 → Jul 2026 overdue | common wart | Mazandaran University of Medical Sciences | Recruiting | No outcome recorded |
| — | NCT04440371 | Jun 2020 → Jul 2023 | generalized vitiligo | Jordan University of Science and Technology | Unknown | No outcome recorded |
| — | NCT02191007 | Nov 2013 → May 2014 | psoriasis | Xijing Hospital | Completed | No outcome recorded |
| — | NCT00871052 | Mar → May 2009 | polymorphic light eruption | Medical University of Graz | Completed | No outcome recorded |
Also used as a comparator or background therapy in 54 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06880042 Comparator | May → Jun 2025 overdue | vitiligo | Dr ayesha wahid | Enrolling by invitation | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT04221906 Comparator | Jan → Mar 2020 | psoriasis | Boston Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03880357 Comparator | Oct 2018 → Mar 2019 | psoriasis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02999776 Comparator | Nov 2016 → Dec 2017 | psoriasis | Pantec Biosolutions AG | Unknown | No outcome recorded |
| Phase 1 | NCT02940002 Comparator | Oct 2016 → Jan 2017 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02680717 Comparator | Mar 2016 → May 2017 | scleroderma | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT03399526 Comparator | Feb → May 2013 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT00358384 Comparator | Sep 2005 → Feb 2006 | psoriasis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06333600 Comparator | May 2023 → Apr 2024 | androgenetic alopecia, skin disorder | Sohag University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02432027 Comparator | Jun → Aug 2015 | psoriasis | Prism Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03069144 Comparator | Jan → Apr 2012 | psoriasis | Haus Bioceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00987870 Comparator | Sep 2009 → Feb 2010 | arthritic joint disease, psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00578370 Comparator | Nov 2007 → Apr 2008 | psoriasis | ISDIN | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07410793 Comparator | Feb 2026 → Feb 2027 expected | psoriasis | Mae Fah Luang University | Recruiting | No outcome recorded |
| Phase 2 | NCT03448081 Comparator | Feb → Nov 2018 | psoriasis | Sienna Biopharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03848806 Comparator | Feb → Jul 2016 | psoriasis | Haus Bioceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02518048 Comparator | Aug 2015 → Jan 2016 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02416258 Comparator | Apr → Jun 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01368887 Comparator | Apr → Nov 2013 | psoriasis | DermiPsor, Ltd. | Suspended | No outcome recorded |
| Phase 2 | NCT01536886 Comparator | May → Sep 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01536938 Comparator | May → Sep 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01301157 Comparator | Feb 2011 → Jan 2012 | psoriasis | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00796211 Comparator | Nov → Dec 2008 | psoriasis | Zalicus | Completed | No outcome recorded |
| Phase 2 | NCT00764751 Comparator | Sep → Dec 2008 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00625326 Comparator | Jan → Dec 2008 | psoriasis | Deltanoid Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT07658508 Comparator | Jul 2025 → Aug 2026 overdue | oral mucosa leukoplakia | Alexandria University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04071106 Comparator | Sep → Dec 2019 | psoriasis | Zagazig University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01763424 Comparator | Jul 2011 → Dec 2012 | psoriasis | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01445886 Comparator | Jan 2011 → Jun 2012 | psoriasis | Yin-ku Lin | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT07453472 Comparator | Apr 2026 → Oct 2028 expected | oral mucosa leukoplakia | All India Institute of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03331523 Comparator | Oct 2017 → Oct 2018 | psoriasis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT02899962 Comparator | Feb 2017 → Jun 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT02644954 Comparator | Jan → Jun 2016 | psoriasis | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT02310646 Comparator | Jan → Jul 2015 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT02132936 Comparator | Jun 2014 → Feb 2015 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01422434 Comparator | Jul 2011 → Apr 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01195831 Comparator | Sep 2010 → Mar 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00670241 Comparator | Apr 2008 → Feb 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00216879 Background | Feb 2005 → Jul 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT04571151 Comparator | Jan → Nov 2021 | psoriasis | Skin Sciences, PLLC | Unknown | No outcome recorded |
| Phase 4 | NCT03866447 Comparator | Oct 2019 → Nov 2020 | acne | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02858713 Background | Jan → Apr 2017 | — | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02533973 Comparator | Sep 2015 → Mar 2018 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 4 | NCT02733874 Comparator | Apr 2015 → Apr 2016 | psoriasis | First Hospital of China Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01745133 Comparator | Jan 2013 → May 2014 | psoriasis | Leon Kircik, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01707043 Comparator | Oct 2012 → Sep 2013 | psoriasis | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT00437255 Comparator | Aug 2006 → Jun 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT06685588 Comparator | Jan 2025 → Jan 2026 overdue | actinic keratosis | St Vincent's University Hospital, Ireland | Not yet recruiting | No outcome recorded |
| — | NCT05954104 Comparator | Jul → Oct 2023 | alopecia areata | Egymedicalpedia | Completed | No outcome recorded |
| — | NCT06011083 Comparator | Aug 2022 → Feb 2023 | psoriasis | Assiut University | Completed | No outcome recorded |
| — | NCT04275024 Background | Apr → Jun 2020 | poisoning, psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT03847441 Comparator | Oct 2017 → Dec 2018 | alopecia areata | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT01413477 Comparator | Aug 2011 → Feb 2012 | allergic contact dermatitis | University of British Columbia | Unknown | No outcome recorded |
| — | NCT00705900 Comparator | Jan 2007 → Nov 2008 | psoriasis | NeoStrata Company, Inc. | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 152 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | calcipotriol | “A Phase 2 Maximal Use Systemic Exposure Study Evaluating the Safety and Efficacy of Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Gel Applied Once Daily...” NCT01229098 ↗93“A phase 2 trial evaluating the safety and efficacy of once daily use of LEO 80185 gel containing calcipotriol 50 mcg/g plus betamethasone 0.5mg/g (as dipropionate) in...” NCT02038569 ↗ “treatment with Xamiol® gel (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) once daily (as required) with Daivonex® scalp solution (calcipotriol 50 mcg/g)...” NCT02533973 ↗ “fixed-dose combination calcipotriol 50 μg/g + betamethasone dipropionate 0.5 mg/g (Cal/BD) cutaneous foam has been approved (Enstilar®, LEO Pharma) in the USA and EU for the...” PMID 32785881 ↗ Aug 2020 “A foam formulation of calcipotriol and betamethasone dipropionate (Cal/BD foam), consisting of calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g, is approved for the...” PMID 32965655 ↗ Sep 2020 “Participants received each of the following six treatments once daily for 18 days: three topical doses (2.3%, 0.8%, 0.23%) of PF-06763809, a vehicle and two active comparators...” PMID 32767679 ↗ Sep 2020 “Daily self-administration of 1 to 5g Daivobet (Calcipotriol 50ug/g +Betamethasone, 0,5mg/g Gel) ointment, which is applied topically once per day for 8 weeks on one...” NCT02999776 ↗ “Effect of Calcipotriol Plus Betamethasone Dipropionate Topical Suspension on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 17 Years) With Scalp Psoriasis” NCT01083758 ↗ “LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks” NCT02132936 ↗ “Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)” NCT04580537 ↗ “The pharmacokinetics of LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate) in Japanese subjects with extensive psoriasis vulgaris.” NCT01768013 ↗ “LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g).” NCT03476746 ↗ “Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week” NCT02310646 ↗ “LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g” NCT03442244 ↗ “Safety and Efficacy of Calcipotriol Plus Betamethasone Dipropionate Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis” NCT01120223 ↗ “Skin Irritation Test of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects” NCT02379793 ↗ “Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)” NCT02518048 ↗ “This group will be treated by topical Vitamin D analogue (Calcipotriol) versus placebo (panthenol).” NCT03866447 ↗ “Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg” NCT02193815 ↗ “LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam” NCT02973776 ↗ “Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension” NCT01188928 ↗ “Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)” NCT01600222 ↗ “Topical application of vitamin D3 analogue (Calcipotriol ointment)” NCT06333600 ↗ “* calcipotriol plus betamethsone dipropionate 0.05%” NCT01313221 ↗ “equivalent to 50.0 µg/g calcipotriol” NCT02668692 ↗ “Calcipotriol” NCT03898583 ↗ |
| Known as | AKVANO | “Calcipotriol/AKVANO, 50 μg/g cutaneous solution” NCT05174598 ↗ |
| Known as | CAL | “Fixed combination calcipotriol as hydrate (Cal) 50 µg/g plus betamethasone as dipropionate (BD) 0.5 mg/g aerosol foam is an alcohol-free treatment for psoriasis.” PMID 27995521 ↗ Apr 20173“Calcipotriol (CAL) enhances thymic stromal lymphopoietin (TSLP), an epithelium-derived cytokine, which promotes antitumor immunity.” NCT06499415 ↗ “combination of calcipotriene (CAL) and betamethasone dipropionate (BDP)” PMID 37490268 ↗ Jul 2023 “calcipotriene \[CAL\]/betamethasone dipropionate \[BDP\] ointment” NCT03462927 ↗ |
| Known as | calcipotriene | “The combination topical suspension of calcipotriene 0.005% and betamethasone dipropionate 0.064% is a first-line treatment for moderate to severe psoriasis vulgaris and is FDA...” NCT01761019 ↗49“Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical...” NCT01707043 ↗ “This study will evaluate the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in...” NCT03506477 ↗ “Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients” NCT04372277 ↗ “Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents” NCT03080545 ↗ “Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation” NCT03899064 ↗ “MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation” NCT03892564 ↗ “Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream” NCT03758365 ↗ “Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064%” NCT03827876 ↗ “MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)” NCT03819218 ↗ “MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream” NCT03802344 ↗ “MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)” NCT03462927 ↗ “calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam” NCT03848871 ↗ “Enstilar Foam (Calcipotriene and Betamethasone Dipropionate)” NCT04227288 ↗ “commercially available calcipotriene 0.005% cream (Dovonex)” PMID 20513160 ↗ 2010 “Calcipotriol (Calcipotriene) is a form of vitamin D.” NCT04329221 ↗ “U0267 is a vitamin D3 analog (calcipotriene) foam.” NCT00689481 ↗ “U0267 is a vitamin D3 analog (calcipotriene) foam.” NCT00688519 ↗ “SORILUX Foam contains calcipotriene 50 mcg/g.” NCT04571151 ↗ |
| Known as | Calcipotriene and betamethasone suspension | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03122353 ↗ |
| Known as | Calcipotriene Hydrate | “Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)” NCT03880357 ↗ |
| Known as | calcipotriol hydrate | “calcipotriol hydrate 52.2 µg/g” NCT03806790 ↗ |
| Known as | Daivonex | “Calcipotriol solution (Daivonex® scalp solution, calcipotriol 50 ug/ml) was purchased from LEO Pharmaceutical Products, Ltd. (Ballerupt, Denmark) and also distributed into 5-ml...” NCT01445886 ↗9“Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.” NCT02976727 ↗ “Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg” NCT02193815 ↗ “Daily application of Daivonex cream (calcipotriol 0.005%)” NCT04221906 ↗ “with Daivonex® scalp solution (calcipotriol 50 mcg/g)” NCT02533973 ↗ “calcipotriol hydrate [Daivonex]” NCT00437619 ↗ |
| Known as | Dovonex | “The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.” NCT03392311 ↗7“two different creams (5-fluorouracil, known as Efudix, and calcipotriol, known as Dovonex)” NCT06685588 ↗ “commercially available calcipotriene 0.005% cream (Dovonex)” PMID 20513160 ↗ 2010 “Dovonex® calcipotriene 0.005%” NCT00820950 ↗ “Dovonex® = calcipotriol” NCT01422434 ↗ “Dovonex” NCT04275024 ↗ |
| Known as | Dovonex (calcipotriol ointment, DIN 01976133 Leo Pharma), | “Dovonex (calcipotriol ointment, DIN 01976133 Leo Pharma),” NCT01413477 ↗ |
| Known as | Sorilux | “The study drugs that will be used in this study are Lexette® (0.05% Halobetasol propionate foam) and Sorilux® (calcipotriene foam).” NCT04571151 ↗ |
| Known as | U0267 | “U0267 is a vitamin D3 analog (calcipotriene) foam.” NCT00689481 ↗1“U0267 is a vitamin D3 analog (calcipotriene) foam.” NCT00688519 ↗ |
| Action | Inhibit | “It inhibits keratinocyte proliferation (cell growth)” NCT03370406 ↗ |
| Modality | Small molecule | “vitamin D analogues such as calcipotriol are used to treat psoriasis.” NCT01413477 ↗ |
| Route | Topical | “once daily topical treatment for up to 8 weeks” NCT00216840 ↗ |
| Target | TSLP | “synergistic impact of TSLP induction by calcipotriol in combination with the cytotoxic effects of 5-FU” NCT04642287 ↗ |